Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.43
-1.4%
$0.47
$0.29
$1.07
$98.63M1.142.46 million shs1.62 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Vaxart, Inc. stock logo
VXRT
Vaxart
0.00%-12.64%+6.59%+38.86%-34.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Vaxart, Inc. stock logo
VXRT
Vaxart
2.2589 of 5 stars
3.51.00.00.02.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00
Buy$3.00594.44% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Vaxart, Inc. stock logo
VXRT
Vaxart
$28.70M3.44N/AN/A$0.26 per share1.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Vaxart, Inc. stock logo
VXRT
Vaxart
-$66.95M-$0.27N/AN/AN/A-122.63%-91.89%-38.40%8/14/2025 (Estimated)

Latest VXRT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
0.64
0.64

Institutional Ownership

CompanyInstitutional Ownership
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Vaxart, Inc. stock logo
VXRT
Vaxart
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120228.31 million222.37 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Vaxart stock logo

Vaxart NASDAQ:VXRT

$0.43 -0.01 (-1.37%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$0.42 -0.02 (-3.94%)
As of 08:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.